Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

11.07.18	Pfizer’s Announces It Will Defer Company’s Price Increases (Businesswire)
11.07.18	Trump says Pfizer is rolling back drug price hikes (Reuters)
10.07.18	Trump Attacks Pfizer For Drug Price Hikes (RTTNews)
09.07.18	MÄRKTE USA/Wall Street legt kräftig zu - Bankenwerte gesucht (Dow Jones)
09.07.18	Trump slams Pfizer after July 1 drug price hikes (Reuters)
03.07.18	Remember When Was The Last Time A New Alzheimer's Drug Was Approved? (RTTNews)
29.06.18	Greenwich Capital Commercial Funding Corp., 2005-GG3 -- Moody's Affirms Four Classes of GCCFC 2005-GG3 (Moodys)
29.06.18	Greenwich Capital Commercial Funding Corp., 2005-GG3 -- Moody's Affirms Four Classes of GCCFC 2005-GG3 (Moodys)
28.06.18	XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for Active Psoriatic Arthritis (Businesswire)
28.06.18	Pfizer Declares 34-Cent Third-Quarter 2018 Dividend (Businesswire)
28.06.18	ACRX Gets EC Nod, AQXP Tanks As LEADERSHIP 301 Fails, ZSAN Catches Eye (RTTNews)
27.06.18	FDA Grants Priority Review For Pfizer's NDA For Glasdegib - Quick Facts (RTTNews)
27.06.18	U.S. FDA Grants Priority Review for Pfizer’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia (Businesswire)
25.06.18	Pfizer Records Overall Survival In Metastatic Breast Cancer Study Using Ibrance (RTTNews)
25.06.18	Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE® (Palbociclib) in HR+, HER2- Metastatic Breast Cancer (Businesswire)
21.06.18	In The Spotlight: Sangamo Therapeutics (RTTNews)
19.06.18	Pfizer Invites Public To View And Listen To Webcast Of July 31 Conference Call With Analysts (Businesswire)
12.06.18	Pfizer Announces Extension of Zithromax® Antibiotic Donation Program through 2025 to Help Eliminate World’s Leading Infectious Cause of Blindness (Businesswire)
07.06.18	Pfizer Granted FDA Priority Review For Talazoparib - Quick Facts (RTTNews)
07.06.18	U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation (Businesswire)
06.06.18	Pfizer To Expand Venture Investing With $600 Mln Commitment To Pfizer Venture (RTTNews)
06.06.18	Pfizer to Expand Venture Investing with $600 Million Commitment to Pfizer Ventures (Businesswire)
04.06.18	Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations (Businesswire)
01.06.18	Pfizer Gets Positive CHMP Opinion For Oncology Biosimilar Trazimera (RTTNews)
01.06.18	Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, TRAZIMERA™ (trastuzumab) (Businesswire)
01.06.18	Intelligent Investor - June 1 (RTTNews)
31.05.18	CRSP Falls On Clinical Hold, PFE Gets FDA Nod, ARWR To Report Data In Nov. (RTTNews)
31.05.18	Pfizer:FDA Oks XELJANZ To Treat Moderately To Severely Active Ulcerative Colitis (RTTNews)
30.05.18	Pfizer-Medikament zur Behandlung von Darmentzündung erhält Genehmigung (Dow Jones)
29.05.18	Pfizer: Xalkori Gets FDA Breakthrough Therapy Designation In Two New Indications (RTTNews)
24.05.18	Pfizer To Pay $23.85 Mln To Resolve Kickback Claims: DoJ (RTTNews)
23.05.18	Pfizer: FDA Grants Breakthrough Therapy Designation For Tafamidis - Quick Facts (RTTNews)
23.05.18	FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy (Businesswire)
22.05.18	A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+ (Businesswire)
22.05.18	Pfizer Begins Phase 1/2 Study To Evaluate Respiratory Syncytial Virus Vaccine (RTTNews)
22.05.18	Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swisscom	527.00	2.33 %	K V
Holcim	95.34	1.21 %	K V
UBS Group	30.42	0.86 %	K V
Roche Hldg G	289.00	0.45 %	K V
Swiss Re	141.65	0.35 %	K V
Givaudan	3’850.00	-1.48 %	K V
Lonza Grp	603.80	-1.50 %	K V
Alcon	82.30	-1.53 %	K V
Geberit	508.00	-1.74 %	K V
Part Grp Hldg	1’386.00	-2.26 %	K V

mehr

06.02.25		Pluszeichen in Europa: STOXX 50 schlussendlich fester
06.02.25		SIX-Handel: SLI beendet die Sitzung weit in der Gewinnzone
06.02.25		Gewinne in Zürich: SMI zum Handelsende mit Kursplus
06.02.25		Handel in London: FTSE 100 letztendlich fester
06.02.25		Handel in Zürich: SPI zum Handelsende im Plus
06.02.25		AstraZeneca-Aktie deutlich im Plus: AstraZeneca übertrifft Prognosen und erwartet Gewinnsteigerung 2025
06.02.25		Börse Zürich: SPI verbucht am Nachmittag Zuschläge

06.02.25

Pluszeichen in Europa: STOXX 50 schlussendlich fester

06.02.25

SIX-Handel: SLI beendet die Sitzung weit in der Gewinnzone

06.02.25

Gewinne in Zürich: SMI zum Handelsende mit Kursplus

06.02.25

Handel in London: FTSE 100 letztendlich fester

06.02.25

Handel in Zürich: SPI zum Handelsende im Plus

06.02.25

AstraZeneca-Aktie deutlich im Plus: AstraZeneca übertrifft Prognosen und erwartet Gewinnsteigerung 2025